BioCentury
ARTICLE | Company News

Epttco Ltd., Vion deal

May 3, 1999 7:00 AM UTC

The companies will research and develop cancer treatments using VION’s Tapet bacterial vectors, which are genetically engineered Salmonella bacteria, to deliver Epttco prodrug activation technology, which uses either nitroreductase or carboxypeptidase G2 enzymes to convert an inactive cytotoxic compound to the active form, at tumor sites. The companies will equally contribute funding and staff. ...